Skip to main content

. 1988 Apr;81(4):233–235. doi: 10.1177/014107688808100418

Reversible pulmonary disease and eosinophilia associated with sulphasalazine.

A Jordan ¹, R E Cowan ¹

PMCID: PMC1291551 PMID: 2897464

233

Images in this article

Figure 1.
on p.234

Figure 2.
on p.234

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Collins J. R. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis. South Med J. 1968 Apr;61(4):354–358. doi: 10.1097/00007611-196804000-00005. [DOI] [PubMed] [Google Scholar]
Eade O. E., Smith C. L., Alexander J. R., Whorwell P. J. Pulmonary function in patients with inflammatory bowel disease. Am J Gastroenterol. 1980 Feb;73(2):154–156. [PubMed] [Google Scholar]
Higenbottam T., Cochrane G. M., Clark T. J., Turner D., Millis R., Seymour W. Bronchial disease in ulcerative colitis. Thorax. 1980 Aug;35(8):581–585. doi: 10.1136/thx.35.8.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
Moseley R. H., Barwick K. W., Dobuler K., DeLuca V. A., Jr Sulfasalazine-induced pulmonary disease. Dig Dis Sci. 1985 Sep;30(9):901–904. doi: 10.1007/BF01309523. [DOI] [PubMed] [Google Scholar]
Wang K. K., Bowyer B. A., Fleming C. R., Schroeder K. W. Pulmonary infiltrates and eosinophilia associated with sulfasalazine. Mayo Clin Proc. 1984 May;59(5):343–346. doi: 10.1016/s0025-6196(12)61431-1. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES